ClinicalTrials.gg
RecruitingNCT06445972Updated Sep 3, 2026

Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)

A Phase 1/2 interventional study of Ramucirumab and Paclitaxel in Gastroesophageal Junction, Gastroesophageal Adenocarcinoma and Esophageal Neoplasms, sponsored by Merck Sharp & Dohme LLC. Recruiting at 46 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-03.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Aug 2024; still recruiting 2 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
210
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 80 studies testing paclitaxel in Esophageal Neoplasms — 11 open to participants now, 18 under way, none of them phase 3. Paclitaxel · Esophageal Neoplasms.

Planned enrollment
11th of 74
210 · median 40
Started
2024
with 3 others
Phase 1/2
9 of 80
2 open now
Primary completion
2028-05
later than 15 of 17 live
Registered
76th of 80
by date

Among the 80 studies testing paclitaxel in Esophageal Neoplasms, this one is the 11th largest by planned enrollment of the 74 interventional ones that give a count, is one of 4 that started in 2024, is one of 9 in phase 1/2, reaches primary completion later than 15 of the 17 other live ones, and was the 76th registered.

Esophageal Neoplasms

1,874 studies on the registry are indexed under Esophageal Neoplasms; 503 are open to participants now.

Browse Esophageal Neoplasms studies →

Open to participants now

11 of the 80 studies testing paclitaxel in Esophageal Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 11 open studies →

About paclitaxel

Paclitaxel: first FDA approval 1992 (TAXOL), first EMA approval 1999. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 388 Esophageal Neoplasms studies recruiting now, 246 (63%) set no upper age limit and 75 (19%) stop at 75 or younger; 20 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 80 studies testing paclitaxel in Esophageal Neoplasms, or all of them as a file.
02

Study summary

This is a phase 1/2 multicenter, open-label umbrella platform study that will evaluate the safety and efficacy of sacituzumab tirumotecan (MK-2870) plus paclitaxel versus ramucirumab plus paclitaxel, and HER3-DXD plus ramucirumab versus ramucirumab plus paclitaxel for the treatment of participants with advanced or metastatic gastric adenocarcinoma, gastroesophageal junction (GEJ) adenocarcinoma, or esophageal adenocarcinoma who have failed 1 prior line of therapy. This is an estimation study, and no formal hypothesis testing will be performed.

Read the detailed description

This is a substudy of the master protocol MK-3475-U06 (KEYMAKER-U06).

03

Conditions studied

  • Gastroesophageal Junction
  • Gastroesophageal Adenocarcinoma
  • Esophageal Neoplasms
  • Esophageal Cancer

Keywords

  • Programmed Cell Death 1 (PD1, PD-1)
  • Programmed Cell Death 1 Ligand 1(PDL1, PD-L1)
  • Programmed Cell Death 1 Ligand 2 (PDL2, PD-L2)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

The main inclusion criteria include but are not limited to the following:

  • Has and/or cytologically confirmed diagnosis of previously treated, (2L) (received first line (1L) treatment) gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, or esophageal adenocarcinoma
  • Has disease or locally advanced, unresectable disease
  • Has experienced documented objective radiographic or clinical disease progression during or after 1L therapy containing any platinum/fluoropyrimidine doublet with or without immunotherapy
  • Tumor tissue must be confirmed as negative for expression (IHC 0/1+ or IHC2+/in situ hybridization negative) as classified by American Society of Clinical Oncology/College of American Pathologists (ASCO-CAP) guidelines
  • Can provide a core/excisional of a tumor lesion not previously irradiated (collected from a biopsy performed after the most recent systemic anticancer therapy regimen)
  • AEs due to previous anticancer therapies must be ≤Grade 1 or baseline (except alopecia and vitiligo). Endocrine-related AEs adequately treated with hormone replacement are acceptable
  • Has performance status of 0 or 1
  • Has a of at least 3 months
  • Participants who are surface antigen (HBsAg) positive are eligible if they have received Hepatitis B Virus (HBV) antiviral therapy for at least 4 weeks, and have undetectable HBV viral load prior to allocation/randomization
  • Participants with history of Virus (HCV) infection are eligible if HCV viral load is undetectable at screening
  • (HIV)-infected participants must have well controlled HIV on antiretroviral therapy

Exclusion criteria

Exclusion Criteria:

The main exclusion criteria include but are not limited to the following:

  • Has squamous cell or undifferentiated gastroesophageal cancer
  • Has experienced weight loss >20% over 3 months before the first dose of study intervention
  • Has history of documented severe dry eye syndrome, severe Meibomian gland disease and/or blepharitis, or severe corneal disease that prevents/delays corneal healing
  • Has Grade ≥2 peripheral neuropathy
  • Has active inflammatory bowel disease requiring medication or previous history of inflammatory bowel disease
  • Has a serious or nonhealing wound or peptic ulcer or bone fracture within 28 days prior to allocation/randomization
  • Has a bowel obstruction, history or presence of inflammatory enteropathy or extensive intestinal resection (hemicolectomy or extensive small intestine resection with chronic diarrhea)
  • Has uncontrolled, significant cardiovascular disease or cerebrovascular disease
  • Has experienced any arterial thrombotic event, including myocardial infarction, unstable angina, cerebrovascular accident, or , within 6 months prior to allocation/randomization
  • Has uncontrolled arterial hypertension ≥150/≥90 mm mercury (Hg)
  • Has accumulation of pleural, ascitic, or pericardial fluid requiring drainage or diuretic drugs within 2 weeks prior to enrollment
  • Has undergone major surgery within 28 days prior to allocation/randomization, or central venous access device placement within 7 days prior to allocation/randomization or planned major surgery following initiation of study treatment
  • Is receiving therapeutic anticoagulation with warfarin, low-molecular weight heparin or similar agents
  • Is receiving chronic therapy with nonsteroidal anti-inflammatory agents or other antiplatelet agents
  • Has a history of deep vein thrombosis, pulmonary embolism, or any other significant thromboembolism during the 3 months prior to allocation/randomization
  • Has significant bleeding disorders, vasculitis, or had a significant bleeding episode from the gastrointestinal (GI) tract within 3 months prior to study entry
  • Has history of GI perforation and/or fistulae within 6 months prior to allocation/randomization
  • -infected participants with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease
  • Has received prior treatment with a trophoblast cell-surface antigen 2 (TROP2)- or HER3-targeted agent, topoisomerase 1 inhibitor-based ADC and/or a topoisomerase 1 inhibitor-based chemotherapy, or any previous systemic therapy targeting vascular endothelial growth factor (VEGF) or the vascular endothelial growth factor receptor (VEGFR) signaling pathways
  • Has received prior systemic anticancer therapy within 4 weeks before the first dose of study intervention
  • Has received prior radiotherapy within 2 weeks of start of study intervention, or has radiation-related toxicities, requiring
  • Has received a live or within 30 days before the first dose of study intervention. Administration of killed vaccines is allowed
  • Has received an agent or has used an investigational device within 4 weeks prior to study intervention administration
  • Has known additional that is progressing or has required active treatment within the past 3 years. Basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ, excluding carcinoma in situ of the bladder, that have undergone potentially curative therapy are not excluded
  • Has known active central nervous system and/or carcinomatous meningitis
  • Has an active infection requiring systemic therapy
  • Has concurrent active (defined as HBsAg positive and/or detectable HBV deoxyribonucleic acid) and virus (defined as anti-HCV antibody positive and detectable HCV ribonucleic acid) infection
  • History of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease, or where suspected ILD or pneumonitis cannot be ruled out by imaging at screening
  • Has severe (Grade ≥3) to MK-2870, or HER3-DXd, any of their , and/or to another biologic therapy
  • Has not adequately recovered from major surgery or have ongoing surgical complications
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
210 participants (estimated)

Study arms

  • Active comparator
    Ramucirumab + Paclitaxel

    Participants receive ramucirumab at 8mg/kg via intravenous (IV) infusion on days 1 and 15 of each 4-week cycle for up to \~60 weeks plus paclitaxel at 80 mg/M\^2 via IV infusion on Days 1, 8, and 15 of each 4-week cycle (3 weeks on and 1 week off) until discontinuation.

    Biological: Ramucirumab · Drug: Paclitaxel

  • Experimental
    Sacituzumab Tirumotecan + Paclitaxel

    Following a 28-day run-in with sacituzumab tirumotecan at 3 mg/kg and 4 mg/kg IV infusion on Days 1 and 15 of a 6-week cycle plus paclitaxel at 80 mg/M\^2 IV infusion on days 1, 8 and 15 of a 4-week cycle, participants receive paclitaxel at 80 mg/M\^2 IV infusion on days 1, 8, 15 of each 4-week cycle (3 weeks on and 1 week off) plus sacituzumab tirumotecan at selected dose IV infusion on days 1, 15, 29 of every 6-week cycle until discontinuation.

    Drug: Paclitaxel · Biological: Sacituzumab Tirumotecan · Drug: Rescue Medications

  • Experimental
    HER3-DXd + Ramucirumab

    Participants receive HER3-DXd via IV infusion on days 1 and 22 of each 6-week cycle plus ramucirumab at 8mg/kg via IV infusion on days 1 and 15 and 29 of each 6-week cycle until discontinuation.

    Biological: Ramucirumab · Drug: Rescue Medications · Biological: HER3-DXd

Interventions

  • BiologicalRamucirumab

    8 mg/kg IV Infusion

  • 80 mg/M\^2 IV infusion

  • 3 mg/kg or 4 mg/kg IV Infusion

    Also known as: MK-2870, SKB264, sac-TMT

  • DrugRescue Medications

    Participants receive rescue medications according to each approved drug's product label. Recommended rescue medications for the Sacituzumab Tirumotecan + Paclitaxel arm include antihistamines (histamine-1 and histamine-2 receptor antagonists), acetaminophen or equivalent, dexamethasone or equivalent infusion, and steroid mouth wash (dexamethasone or equivalent) and rescue medications for the HER3-DXd + ramucirumab arm include 5-HT3-receptor antagonist, NK-1 receptor antagonist, and corticosteroids.

  • BiologicalHER3-DXd

    IV Infusion

    Also known as: patritumab deruxtecan, MK-1022, U3-1402

06

What researchers measure

Primary outcomes

  1. Percentage of Participants who Experience Dose Limiting Toxicities (DLTs) During the Safety Lead-In Phase

    DLTs are defined as any drug-related adverse event (AE) according to the National Cancer Institute Common Terminology for Adverse Events (NCI CTCAE) Version 5.0, observed during the DLT evaluation period that results in a change to a given dose or a delay in initiating the next cycle. The percentage of participants who experience at least one DLT will be presented.

    Time frame: Up to ~28 days

  2. Percentage of Particiapants who Experience an Adverse Event (AE) During the Safety Lead-In Phase

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The percentage of participants who discontinued study intervention due to an AE will be presented.

    Time frame: Up to ~60 days

  3. Percentage of Participants who Discontinue Study Intervention Due to an AE During the Safety Lead-In Phase

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The percentage of participants who discontinued study intervention due to an AE will be presented.

    Time frame: Up to ~28 days

  4. Objective Response Rate (ORR)

    ORR is defined as the percentage of participants with Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1). The percentage of participants who experience CR or PR as assessed by Blinded Independent Central Review (BICR) will be presented.

    Time frame: Up to ~28 months

Secondary outcomes

  1. Progression Free Survival (PFS)

    PFS is defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurs first as assessed by RECIST 1.1. PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. PFS as assessed by BICR will be presented.

    Time frame: Up to ~50 months

  2. Duration of Response (DOR)

    For participants who demonstrate a confirmed Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1, DOR is defined as the time from first documented evidence of CR or PR until progressive disease (PD) or death. Per RECIST 1.1, PD is defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered PD. DOR as assessed by BICR will be presented.

    Time frame: Up to ~50 months

  3. Overall Survival (OS)

    OS is defined as the time from the date of randomization to the date of death from any cause. OS will be presented.

    Time frame: Up to ~50 months

  4. Percentage of Particiapants who Experience an AE During the Efficacy Phase

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The percentage of participants who discontinued study intervention due to an AE will be presented.

    Time frame: Up to ~50 months

  5. Percentage of Participants who Discontinue Study Intervention Due to an AE During the Efficacy Phase

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The percentage of participants who discontinued study intervention due to an AE will be presented.

    Time frame: Up to ~50 months

  6. Incidence of sacituzumab tirumotecan anti-drug antibody (ADA)

    In participants treated with sacituzumab tirumotecan the immunogenicity of sacituzumab tirumotecan ADA response will be evaluated with validated immunogenicity assays.

    Time frame: Up to ~50 months

  7. Incidence of HER3-DXd ADA

    In participants treated with HER3-DXd, the immunogenicity of HER3-DXd ADA response will be evaluated with validated immunogenicity assays.

    Time frame: Up to ~50 months

07

Study locations

44 of 46 sites recruiting
  • University of Arizona Cancer Center-University of Arizona Cancer Center ( Site 8927)
    Tucson, Arizona 85719, United States
    Recruiting
    • Study Coordinator · Contact520-621-2449
  • UCLA Hematology/Oncology - Santa Monica ( Site 8905)
    Los Angeles, California 90404, United States
    Recruiting
    • Study Coordinator · Contact310-570-1453
  • Norton Cancer Institute - Downtown ( Site 8900)
    Louisville, Kentucky 40202, United States
    Completed

    Not enrolling at this site — choose another above.

  • The Cancer and Hematology Centers ( Site 8912)
    Grand Rapids, Michigan 49503, United States
    Recruiting
    • Study Coordinator · Contact616-975-3065
  • Hematology-Oncology Associates of Central NY, P.C. ( Site 8925)
    East Syracuse, New York 13057, United States
    Recruiting
    • Study Coordinator · Contact315-472-7504
  • Columbia University Irving Medical Center-CUIMC Herbert Irving Comprehensive Cancer Center Clinical ( Site 8907)
    New York, New York 10032, United States
    Completed

    Not enrolling at this site — choose another above.

  • UPMC Hillman Cancer Center-UPMC ( Site 8904)
    Pittsburgh, Pennsylvania 15232, United States
    Recruiting
    • Study Coordinator · Contact816-898-9413
  • University of Texas MD Anderson Cancer Center ( Site 8920)
    Houston, Texas 77030, United States
    Recruiting
    • Study Coordinator · Contact833-589-0868
  • Liga Norte Riograndense Contra o Câncer ( Site 8303)
    Natal, Rio Grande do Norte 59062-000, Brazil
    Recruiting
    • Study Coordinator · Contact+558440095595
  • Hospital Nossa Senhora da Conceição ( Site 8301)
    Porto Alegre, Rio Grande do Sul 91350-200, Brazil
    Recruiting
    • Study Coordinator · Contact+5551993590437
  • IBCC - Instituto Brasileiro de Controle do Câncer ( Site 8304)
    São Paulo, São Paulo 03102-002, Brazil
    Recruiting
    • Study Coordinator · Contact551144500300
  • ICESP - INSTITUTO DO CÂNCER DO ESTADO DE SÃO PAULO ( Site 8300)
    São Paulo, 01246-000, Brazil
    Recruiting
    • Study Coordinator · Contact551138932000
  • Clínica Puerto Montt ( Site 8409)
    Port Montt, Los Lagos Region 5500243, Chile
    Recruiting
    • Study Coordinator · Contact+56652484800
  • Centro de Investigación del Maule ( Site 8408)
    Talca, Maule Region 3481349, Chile
    Recruiting
    • Study Coordinator · Contact56712981241
  • FALP-UIDO ( Site 8400)
    Santiago, Region M. de Santiago 7500921, Chile
    Recruiting
    • Study Coordinator · Contact56224205098
  • Centro de Oncología de Precisión-Oncology ( Site 8404)
    Santiago, Region M. de Santiago 7560908, Chile
    Recruiting
    • Study Coordinator · Contact56225189885
  • Clínica UC San Carlos de Apoquindo ( Site 8405)
    Santiago, Region M. de Santiago 7620002, Chile
    Recruiting
    • Study Coordinator · Contact56934271024
  • Bradfordhill-Clinical Area ( Site 8401)
    Santiago, Region M. de Santiago 8420383, Chile
    Recruiting
    • Study Coordinator · Contact56229490970
  • Bradford Hill Norte ( Site 8407)
    Antofagasta, 1263521, Chile
    Recruiting
    • Study Coordinator · Contact56442023631
  • Beijing Cancer hospital-Digestive Oncology ( Site 7500)
    Beijing, Beijing Municipality 100142, China
    Recruiting
    • Study Coordinator · Contact(010)88196317
  • The 900th Hospital of the Joint Logistics Support Force of the Chinese People's Liberation Army ( Site 7501)
    Fuzhou, Fujian 350025, China
    Recruiting
    • Study Coordinator · Contact0591-22859606
  • The First Affiliated hospital of Xiamen University ( Site 7503)
    Xiamen, Fujian 361003, China
    Recruiting
    • Study Coordinator · Contact0592-2139767
  • Henan Cancer Hospital ( Site 7504)
    Zhengzhou, Henan 450000, China
    Recruiting
    • Study Coordinator · Contact400-0371-818
  • The First Affiliated Hospital of Nanchang University ( Site 7514)
    Nanchang, Jiangxi 330000, China
    Recruiting
    • Study Coordinator · Contact0791-86427234
  • Fudan University Shanghai Cancer Center ( Site 7513)
    Shanghai, Shanghai Municipality 200032, China
    Recruiting
    • Study Coordinator · Contact(021)6417 5590
  • Xinjiang Medical University Cancer Hospital - Urumqi ( Site 7506)
    Ürümqi, Xinjiang 841100, China
    Recruiting
    • Study Coordinator · Contact(+86) 0991-7819113
  • Sir Run Run Shaw Hospital of Zhejiang University School of Medicine ( Site 7510)
    Hangzhou, Zhejiang 310016, China
    Recruiting
    • Study Coordinator · Contact0571 8609 0073
  • Centre Hospitalier Régional Universitaire de Brest - Hôpital-Institut de cancérologie et hématologi ( Site 7104)
    Brest, Finistere 29200, France
    Recruiting
    • Study Coordinator · Contact33298223428
  • CIC. ( Site 7100)
    Lille, Nord 59037, France
    Recruiting
    • Study Coordinator · Contact+33320445461
  • Pitie Salpetriere University Hospital-Hepato-Gastro-Enterology ( Site 7102)
    Paris, Île-de-France Region 75013, France
    Recruiting
    • Study Coordinator · Contact+331 42 16 10 41
  • NCT-Department of Medical Oncology ( Site 8809)
    Heidelberg, Baden-Wurttemberg 69120, Germany
    Recruiting
    • Study Coordinator · Contact+49 62215637784
  • HOPE Hamburg/Norddeutsches Studienzentrum fuer Innovative Onkologie ( Site 8807)
    Erdgeschoss, Free and Hanseatic City of Hamburg 22297, Germany
    Recruiting
    • Study Coordinator · Contact+4940360352246
  • Universitaetsklinikum Duesseldorf-Gastroenterology, Hepatology and Infectiology ( Site 8802)
    Düsseldorf, North Rhine-Westphalia 40225, Germany
    Recruiting
    • Study Coordinator · Contact+492118108751
  • IRCCS - Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori"-Oncologia Medica ( Site 7207)
    Meldola, Emilia-Romagna 47014, Italy
    Recruiting
    • Study Coordinator · Contact0543739100
  • Fondazione IRCCS Istituto Nazionale dei Tumori-Struttura Complessa Oncologia Medica 1 ( Site 7200)
    Milan, Lombardy 20133, Italy
    Recruiting
    • Study Coordinator · Contact0223903807
  • Azienda Ospedaliero Universitaria Pisana ( Site 7206)
    Pisa, Tuscany 56126, Italy
    Recruiting
    • Study Coordinator · Contact050992454
  • Ospedale San Raffaele-Oncologia Medica ( Site 7202)
    Milan, 20132, Italy
    Recruiting
    • Study Coordinator · Contact+390226437615
  • Oslo universitetssykehus, Radiumhospitalet ( Site 8501)
    Oslo, 0379, Norway
    Recruiting
    • Study Coordinator · Contact4723026600
  • Asan Medical Center-Department of Oncology ( Site 7901)
    Seoul, 05505, South Korea
    Recruiting
    • Study Coordinator · Contact+82230103217
  • Samsung Medical Center-Division of Hematology/Oncology ( Site 7900)
    Seoul, 06351, South Korea
    Recruiting
    • Study Coordinator · Contact82234101795
  • Hôpitaux Universitaires de Genève (HUG) ( Site 8701)
    Geneva, Canton of Geneva 1211, Switzerland
    Recruiting
    • Study Coordinator · Contact+41 22 372 29 01
  • Kantonsspital Graubünden-Medizin ( Site 8700)
    Chur, Kanton Graubünden 7000, Switzerland
    Recruiting
    • Study Coordinator · Contact+41 81 256 61 11
  • China Medical University Hospital ( Site 8007)
    Taichung, 404332, Taiwan
    Recruiting
    • Study Coordinator · Contact886422052121x15057
  • National Cheng Kung University Hospital ( Site 8001)
    Tainan, 704, Taiwan
    Recruiting
    • Study Coordinator · Contact+88662353535x4559
  • National Taiwan University Hospital-Oncology ( Site 8000)
    Taipei, 10048, Taiwan
    Recruiting
    • Study Coordinator · Contact+88623123456x267852
  • Taipei Veterans General Hospital ( Site 8005)
    Taipei, 112, Taiwan
    Recruiting
    • Study Coordinator · Contact+88628717270x131
08

References and documents

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2024 (actual). Primary completion is estimated for May 2028, 45 months after the start.

Of 74 phase 1/2 interventional studies under Esophageal Neoplasms, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 43 and three quarters within 92. This study's planned 45 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 31, 2024
First posted
Jun 6, 2024
StartActual
Aug 7, 2024
Primary completionEst.
May 9, 2028
CompletionEst.
Aug 8, 2030
Last update
Sep 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06445972
Collaborators
Daiichi Sankyo
Responsible party
Sponsor
First posted
Jun 6, 2024
Start date
Aug 7, 2024
Primary completion
May 9, 2028 (estimated)
Completion
Aug 8, 2030 (estimated)
Last update
Sep 3, 2026

Study contacts

Toll Free Number
Contact
Trialsites@msd.com
1-888-577-8839
Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ramucirumab · Paclitaxel · Sacituzumab tirumotecan · Patritumab deruxtecan

Start the discussion